Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Simon J. Hollingsworth(AstraZeneca (Japan))
Cited by 134
Related Papers
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
|Nature Medicine|2023|372
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
|CA A Cancer Journal for Clinicians|2011|209
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
|Clinical Cancer Research|2011|168
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers
|Cancer Discovery|2020|134
Phase 2 study of pembrolizumab in patients with advanced rare cancers
|Journal for ImmunoTherapy of Cancer|2020|130